PHARMACEUTICAL PREPARATION CONTAINING RECOMBINANT HCG (HUMAN CHORIONIC GONADOTROPIN HORMONE) Russian patent published in 2020 - IPC C07K14/59 C12P21/02 A61K38/24 A61P15/08 A61P5/06 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: group of inventions k relates to chorionic gonadotropic hormone. Disclosed are a pharmaceutical composition having human chorionic gonadotropin (hCG) activity, containing recombinant hCG (rhCG) containing α2,3-linked sialic acid and α2,6-linked sialic acid, and a pharmaceutically acceptable carrier. RhCG is produced or expressed in a human cell line possessing endogenous activity of α2,6-sialyltransferase and transfected with the hCG alpha and beta subunit genes and the α2,3-sialyltransferase genome α. Also disclosed are a pharmaceutical composition having human chorionic gonadotropin (hCG) and follicle-stimulating hormone (FSH) activities, containing rhCG containing α2,3-linked sialic acid and α2,6-linked sialic acid, and FSH. Method for preparing a pharmaceutical composition containing said rhCG involves a step for producing or expressing rhCG in a human cell line showing endogenous activity of α2,6-sialyltransferase and transfected with the hCG alpha and beta subunit genes and the α2,3-sialyltransferase genome α.

EFFECT: invention enables to obtain hCG having activity of 27477 IU/mg, with a relative amount of mono-, two-, three- and four (antenna) sialylated structures in following ratios (1S:2S:3S:4S): 1/5–1 : 35–40 : 25/10–7 : 1/2–1 and with content of sialic acid from 15 mol/mol to 25 mol/mol, for example 191/10 mol/mol.

7 cl, 6 dwg, 1 tbl, 11 ex